Abstract | BACKGROUND: MATERIALS AND METHODS: In this study the synergistic effects of administering CA1P in combination with cisplatin (CPL) in a well-differentiated transplantable murine colon model (MAC 29) was evaluated. RESULTS: CA1P at 100 mgkg-1 significantly potentiated the anti-tumour effects of CPL. The effect with CPL was similar to that seen for CA1P at its maximum tolerated dose (MTD) alone. CONCLUSION: These data demonstrate that the combination of CA1P and CPL has significant preclinical antitumour activity against a transplantable murine adenocarcinoma model that is related to the antivascular effects of CA1P.
|
Authors | S D Shnyder, P A Cooper, G R Pettit, J W Lippert 3rd, M C Bibby |
Journal | Anticancer research
(Anticancer Res)
2003 Mar-Apr
Vol. 23
Issue 2B
Pg. 1619-23
ISSN: 0250-7005 [Print] Greece |
PMID | 12820431
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Angiogenesis Inhibitors
- Antineoplastic Agents
- Stilbenes
- combretastatin A-1
- Cisplatin
|
Topics |
- Adenocarcinoma, Mucinous
(blood supply, drug therapy, pathology)
- Angiogenesis Inhibitors
(administration & dosage, pharmacology)
- Animals
- Antineoplastic Agents
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cisplatin
(administration & dosage, pharmacology, therapeutic use)
- Colonic Neoplasms
(pathology)
- Drug Screening Assays, Antitumor
- Drug Synergism
- Female
- Mice
- Mice, Inbred Strains
- Neoplasm Transplantation
- Stilbenes
(administration & dosage, pharmacology)
|